Expert Interview
A Second Look: Discussing the recent FDA approval of Cobenfy (KarXT), an oral antipsychotic developed by BMS and Karuna for the treatment of schizophrenia.
Ticker(s): BMY, KRTXInstitution: Private Practice, Los Gatos CA
- Private practice psychiatrist with research background, extensive industry collaboration, and frequent patient/peer educational activities.
- Currently manages 200 patients with depression, 50 patients with bipolar, and 25 patients with acute agitation per month.
- Previously served as an adjunct faculty member at the University of California at San Francisco Department of Psychiatry and the Stanford University Department of Psychiatry.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
